Low-dose aspirin combined with low-molecular-weight heparin (LMWH) during pregnancy is just as safe and effective as aspirin with unfractionated heparin (UFH) for preventing recurrent pregnancy loss due to antiphospholipid syndrome, according to a prospective, controlled, multicenter pilot study.
Low-dose aspirin combined with low-molecular-weight heparin (LMWH) during pregnancy is just as safe and effective as aspirin with unfractionated heparin (UFH) for preventing recurrent pregnancy loss due to antiphospholipid syndrome, according to a prospective, controlled, multicenter pilot study.
The study included 50 women. Of 25 who received LMWH, 21 (84%) delivered a viable infant and 4 (16%) miscarried. Among 25 who received UFH, 20 (80%) delivered a viable infant and five (20%) miscarried. The differences were not statistically significant. No major bleeding episodes occurred during pregnancy or birth, and no cases of deep venous thrombosis, thrombocytopenia, preeclampsia, gestational diabetes, or bone fractures occurred in either group.
The investigators concluded that a large, randomized trial is now needed to further determine any differences in outcomes.
Link between prenatal air pollution and reduced lung function in offspring reported
July 25th 2024Higher prenatal exposure to PM2.5 pollution is associated with reduced lung volume and airflow limitation in children, highlighting the critical impact of air pollution on in utero lung development.
Read More
Cut costs observed from out-of-home care in children with prenatal substance exposure
July 24th 2024A recent study reveals that while children exposed to maternal substance use face higher hospital costs up to age 20 years, out-of-home care significantly mitigates this financial burden.
Read More
Global progress in neonatal tetanus elimination from 2000 to 2022
July 18th 2024Incorporating maternal and neonatal tetanus elimination strategies into national immunization activities is crucial for sustaining elimination and reducing neonatal mortality worldwide, as highlighted by the latest CDC report.
Read More
PreTRM test shows efficacy in reducing severe neonatal morbidity and mortality
July 18th 2024The PreTRM test, a blood-based biomarker test for predicting preterm birth risk, has demonstrated significant efficacy in lowering severe neonatal morbidity and mortality, as reported by Sera Prognostics Inc.
Read More